TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19894376

Group type: EXPERIMENTAL
Intervention: Chinese decoction, ligustrazin hydrochloride injection, and He‐Ne laser therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vitamin E and Vitamin C plus external application of 20% Azelaic acid cream
Number of subjects: 90
Study: 17040925

Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 6045

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6045
Study: 12719047

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% (10 mL) and morphine 0.1% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% plus morphine 0.025% (5 mL/hr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: bupivacaine 0.25% (10 mL) and saline 0.9% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% (5 mL/hr)
Number of subjects: 40
Study: 10750913

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) procedure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Umbilical venous catheterization (UVC) procedure
Number of subjects: 42
Study: 9010708

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1291405

Group type: EXPERIMENTAL
Intervention: 20 mg p.o. omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 mg i.v. omeprazole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg i.v. omeprazole
Number of subjects: 8
Study: 6698373

Group type: EXPERIMENTAL
Intervention: Acetaminophen (2600 mg orally 1 hour before aspirin or ethanol)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aspirin (1300 mg) or Ethanol (20% vol/vol)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Indomethacin (50 mg orally 12 hours and 1 hour before acetaminophen)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Indomethacin alone
Number of subjects: 5
Study: 30822612

Group type: EXPERIMENTAL
Intervention: Prism adaptation to a leftward optical deviation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 30566006

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9338
Study: 29101447

Group type: EXPERIMENTAL
Intervention: Short video intervention
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Seminar involving direct contact with a service user
Number of subjects: 254

Group type: COMPARATOR
Intervention: Informational leaflet
Number of subjects: 254
Study: 26267853

Group type: EXPERIMENTAL
Intervention: Replacing the existing lens with a new lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Removing and reapplying the same lens
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Performing a 'scleral swish'
Number of subjects: 30

Group type: COMPARATOR
Intervention: No action (control)
Number of subjects: 30
Study: 24006504

Group type: EXPERIMENTAL
Intervention: Pirarubicin instillation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 108
Study: 21934487

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Both RFA and EVLT
Number of subjects: 159
Study: 19146517

Group type: EXPERIMENTAL
Intervention: Self-worth therapy (30 minutes, once a week for 4 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no therapy, 30 minutes of chatting once a week for 4 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Self-worth therapy
Number of subjects: 63
Study: 16446080

Group type: COMPARATOR
Intervention: Regular environmental conditions (20.2 degrees C, 40% relative humidity)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Humid environmental conditions (19.9 degrees C, 95% relative humidity)
Number of subjects: 20
Study: 14578394

Group type: EXPERIMENTAL
Intervention: Reverse geometry design CRT (Dk=100) rigid lenses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alignment tricurve rigid lens (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control lens
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test lens
Number of subjects: 20
Study: 10784481

Group type: EXPERIMENTAL
Intervention: 60 g/day of glycine added to clozapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9075807

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine (NO-synthase inhibitor)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine (NO precursor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 20
Study: 8491275

Group type: EXPERIMENTAL
Intervention: Sinusoidal treadmill movement at frequencies of 0.5, 0.3, and 0.25 Hz with a constant amplitude of +/- 12 cm.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinusoidal treadmill movement with eyes open or closed.
Number of subjects: 0
Study: 3703632

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with human milk protein (0.9 g/dL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Plain human milk (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with medium-chain triglycerides (1 g/dL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with both protein and medium-chain triglycerides
Number of subjects: 44

Group type: COMPARATOR
Intervention: Human milk without protein supplementation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with protein
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Serum albumin concentration correlation with weight gain
Number of subjects: 44
Study: 31982090

Group type: EXPERIMENTAL
Intervention: Children with congenital diaphragmatic hernia (CDH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (randomly selected children without CDH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female cases with CDH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males with CDH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with CDH
Number of subjects: 0
Study: 29722893

Group type: EXPERIMENTAL
Intervention: Sleep restriction (6 hr time in bed)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sleep extension (10 hr time in bed)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 35
Study: 27579509

Group type: EXPERIMENTAL
Intervention: Mailed motivational, individually tailored postcards (n = 54)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: No postcards (n = 63)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (n = 64)
Number of subjects: 117
Study: 24679395

Group type: EXPERIMENTAL
Intervention: Collaborative care programme
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 338
Study: 22353807

Group type: EXPERIMENTAL
Intervention: Exemestane after 2-3 years of tamoxifen
Number of subjects: 582

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 582
Study: 20181785

Group type: EXPERIMENTAL
Intervention: Nutritional advice alone
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Nutritional advice plus vouchers for fruits and vegetables
Number of subjects: 295

Group type: COMPARATOR
Intervention: Control group (Nutritional advice alone)
Number of subjects: 295
Study: 18394770

Group type: EXPERIMENTAL
Intervention: Mandibular implant overdentures (IODs)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Conventional dentures (CDs)
Number of subjects: 256
Study: 16007391

Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham smoking
Number of subjects: 8
Study: 12771115

Group type: EXPERIMENTAL
Intervention: CRT group (ICD activated, CRT on)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Control group (ICD activated, CRT off)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 369
Study: 10907343

Group type: EXPERIMENTAL
Intervention: Combination therapy of bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusive dressing therapy with bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group II)
Number of subjects: 0
Study: 8054072

Group type: EXPERIMENTAL
Intervention: Intermittent transdermal application of nitroglycerin (15 hours/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Continuous transdermal application of nitroglycerin (24 hours/day)
Number of subjects: 12
Study: 2681872

Group type: EXPERIMENTAL
Intervention: Whole brain irradiation (40 Gy)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Local irradiation (total 56 Gy/28 f/6 weeks)
Number of subjects: 49
Study: 770083

Group type: EXPERIMENTAL
Intervention: 800 mg azapropazone per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: 100 mg indomethacin per day
Number of subjects: 50
Study: 31386163

Group type: EXPERIMENTAL
Intervention: ItchyQoL questionnaire
Number of subjects: 130
Study: 28279433

Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation target (85‐89%)
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Higher oxygen saturation target (91%‐95%)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Lower achieved oxygen saturation (≤92%)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Increased incidence of intermittent hypoxemia events
Number of subjects: 1054
Study: 26208959

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 mg/kg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 23599046

Group type: EXPERIMENTAL
Intervention: D-Cycloserine (50 mg before each of five exposure sessions)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo (before each of five exposure sessions)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 20648212

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumbar intraarticular facet joint injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumbar interlaminar epidural injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caudal epidural steroids for conditions other than disc herniation or radiculitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sacroiliac joint injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intradiscal electrothermal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic adhesiolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic lumbar facet joint nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections in disc herniation or radiculitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis in post lumbar surgery syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transforaminal epidural injections in radiculitis
Number of subjects: 0
Study: 17901215

Group type: EXPERIMENTAL
Intervention: Physician communication behaviors (careful listening, inquiring about at-home management, nonverbal attention, interactive conversation, tailoring short-term goals, long-term therapeutic plan)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Physician communication behaviors (interactive conversation, short-term goals, criteria for decision making, long-term treatment plan, tailoring according to needs)
Number of subjects: 452
Study: 16616235

Group type: EXPERIMENTAL
Intervention: Elevated D-dimer (highest tertile)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Baseline D-dimer
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Baseline CRP (highest tertile)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Primary end point (composite of ABI progression, CDS progression, stroke, myocardial infarction, amputation, and death from cardiovascular disease)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Baseline D-dimer and CRP
Number of subjects: 332
Study: 14526281

Group type: EXPERIMENTAL
Intervention: Scripted verbal query
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detailed written permission slip
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (current practice)
Number of subjects: 0
Study: 10868720

Group type: EXPERIMENTAL
Intervention: Le Bon Départ treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sensory Integration treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Treatment 1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Treatment 2
Number of subjects: 6
Study: 9106374

Group type: EXPERIMENTAL
Intervention: Nortriptyline for 6 weeks (with possible adjunctive lithium)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenelzine for 6 weeks (with possible lithium augmentation)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy or fluoxetine for 6 weeks (with possible lithium augmentation)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Overall treatment response
Number of subjects: 101
Study: 1583265

Group type: EXPERIMENTAL
Intervention: Allen figure
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Broken Wheel
Number of subjects: 34
Study: 3896663

Group type: EXPERIMENTAL
Intervention: Pivampicillin (500 mg or 1 g twice daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amoxycillin (250 mg or 500 mg 3-times daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 43
Study: 31429514

Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 27
Study: 26919833

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day) and Naoxintong Capsule (1.6 g thrice a day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (international normalized ratio 2.0-3.0)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Aspirin combined with NXT and warfarin
Number of subjects: 151
Study: 27511181

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment (titrated to trough levels of 5-10 ng/mL)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sirolimus treatment (for children who reached target trough levels)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard-care period
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cognitive development
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 23
Study: 24652518

Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab treatment
Number of subjects: 835
Study: 22972872

Group type: EXPERIMENTAL
Intervention: β-blockers (metoprolol)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Pooled analysis of β-blockers
Number of subjects: 153
Study: 19819079

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18008230

Group type: EXPERIMENTAL
Intervention: Valacyclovir at 500 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16238910

Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation (AFIB) patients
Number of subjects: 3944
Study: 12147008

Group type: EXPERIMENTAL
Intervention: Scanning and cueing approach
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Contralesional limb activation approach
Number of subjects: 7
Study: 10411846

Group type: EXPERIMENTAL
Intervention: Primary stenting with the heparin‐coated Palmaz‐Schatz stent
Number of subjects: 410

Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 410
Study: 7738626

Group type: EXPERIMENTAL
Intervention: Dopamine (2 micrograms/kg/min continuous infusion over 48 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 42
Study: 1876891

Group type: EXPERIMENTAL
Intervention: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Lidocaine (LID) 2 mg/min constant-rate infusion after a bolus of LID 100 mg + Magnesium Sulfate (M) 2.5 mg/min (Group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lidocaine (LID) alone (Group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lidocaine (LID) + Magnesium (Group B)
Number of subjects: 34
Study: 6348397

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Kidney Allotransplantation (KT)
Number of subjects: 27
Study: 29955932

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 28475465

Group type: EXPERIMENTAL
Intervention: Diet group (6 days of food restriction)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (maintained body weight)
Number of subjects: 11
Study: 25307158

Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 70
Study: 25134291

Group type: EXPERIMENTAL
Intervention: GnRH analogues (subcutaneous triptorelin depot injection) before hydrothermal endometrial ablation (HTA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no presurgical treatment)
Number of subjects: 30
Study: 22481014

Group type: EXPERIMENTAL
Intervention: Curcuminoids 4 g/day starting 3 days before surgery until 5 days after surgery
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 121
Study: 19859699

Group type: EXPERIMENTAL
Intervention: Glucose tablets
Number of subjects: 928

Group type: COMPARATOR
Intervention: Placebo (sorbitol) tablets
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Glucose tablets with other medication (NRT/bupropion)
Number of subjects: 928

Group type: COMPARATOR
Intervention: Placebo with other medication (NRT/bupropion)
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Glucose tablets without other medication
Number of subjects: 928

Group type: COMPARATOR
Intervention: Placebo without other medication
Number of subjects: 928
Study: 16981901

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg once daily for 14 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Midazolam (2 mg oral and 1 mg i.v., 1 day apart)
Number of subjects: 18
Study: 16275518

Group type: EXPERIMENTAL
Intervention: Myocardial velocity imaging-derived RV IVRT (IVRT')
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Heart rate-corrected IVRT' derived from the basal RV free wall segment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tricuspid regurgitation-derived PAP systolic
Number of subjects: 33
Study: 12187217

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral roots (15 Hz, 50% intensity output for 5 seconds per minute for 30 minutes)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active stimulation group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation group
Number of subjects: 48
Study: 9925698

Group type: COMPARATOR
Intervention: Control group (n = 95)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cancer at the distal bile duct group (n = 9)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Bile duct stone group (n = 56)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Obstructive jaundice group (n = 17)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Cancer extension to the common hepatic duct group (n = 4)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Sclerosing cholangitis group (n = 2)
Number of subjects: 183
Study: 7485932

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 811

Group type: COMPARATOR
Intervention: Parenteral morphine
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Previous oral herpes
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Pruritus
Number of subjects: 811
Study: 2372330

Group type: EXPERIMENTAL
Intervention: Vibratory acoustic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vibratory acoustic stimulation)
Number of subjects: 0
Study: 369868

Group type: EXPERIMENTAL
Intervention: Paracetamol (1.0 g x 4 for 2 days, then 0.5 g x 4 for the next 2 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 24
Study: 31118315

Group type: EXPERIMENTAL
Intervention: Data elements for electronic medical records (EMRs) for mental disorders
Number of subjects: 50
Study: 28148492

Group type: EXPERIMENTAL
Intervention: Rest-1 (1 min rest between sprints)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rest-5 (5 min rest between sprints)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups (Rest-1 and Rest-5)
Number of subjects: 14
Study: 25975702

Group type: EXPERIMENTAL
Intervention: Experimental training program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24051231

Group type: EXPERIMENTAL
Intervention: Theanine (200 mg, twice a day, after breakfast and lunch)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 22151785

Group type: EXPERIMENTAL
Intervention: Garlic (1200 μg allicin, three times daily)
Number of subjects: 117

Group type: COMPARATOR
Intervention: d‐penicillamine (250 mg, three times daily)
Number of subjects: 117
Study: 19689918

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 17482846

Group type: EXPERIMENTAL
Intervention: Reduced anticoagulation (INR target 1.8)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Full anticoagulation (INR target 2.5 or more)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 131